Navigation Links
HistoRx Receives Key Patent on Application of AQUA(R) Technology to Personalized Medicine
Date:5/12/2010

NEW HAVEN, Conn., May 12 /PRNewswire/ -- HistoRx , Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for determining a cancer patient's prognosis based on sub-cellular localization of biomarkers.  U.S. Patent No. 7,709,222 is issued to Yale University and inventors David Rimm, Bob Camp, Mark Gustavson and Greg Tedeschi, and is exclusively licensed to HistoRx.

Use of tissue biomarkers to characterize a patient's cancer is a crucial element of personalized cancer care.  To improve patient survival rates, therapies in the oncology marketplace are being combined with predictive biomarkers to help select patients who will respond to specific drugs. The claims issued in HistoRx's new patent pertain to quantification of thymidylate synthase (TS), a well-known enzyme, in sub-cellular compartments -- that is, the nucleus vs. cytoplasm of tumor cells -- and using the ratio to determine a patient's prognosis and responsiveness to specific treatments. The results from this test can be used to prescribe currently available therapeutics, making the test immediately relevant to oncologists.   

The invention was only possible through the use of HistoRx's proprietary AQUA® technology to quantify TS in cellular compartments of tumor cells from patients with colon cancer.  AQUA technology is an automated, quantitative IHC testing method that enables measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis.  Such precise determination of first, the location within the tumor cell and second, the amount in each location is not possible with conventional testing methods, such as standard immunohistochemistry (IHC). AQUA analysis is used in cancer research by twenty leading academic centers worldwide, is part of the clinical development plans for more than ten drug candidates from major pharma companies, and has been cited in more than 90 peer-reviewed publications.  The first use of AQUA technology in the clinical diagnostic setting is expected later in 2010 with the launch by Genoptix Inc. (Nasdaq: GXDX) of diagnostic tests based on AQUA technology licensed from HistoRx.

"This patent demonstrates AQUA technology's superiority to IHC by quantifying the ratio of TS in two sub-cellular compartments to identify patients who will respond to common first line therapeutics," said Rana K. Gupta, CEO of HistoRx. "Secondly, other TS tests available today are not standardized to give physicians confidence in the biomarker.  AQUA technology is the foundation for the next generation of protein biomarker tests, addressing the clinical need for reliable results and quantifying biomarkers in context of their location."

"The use of a quantitative expression ratio between cellular compartments is a novel approach that is currently only possible with AQUA® technology and can provide enhanced prognostic and predictive information for oncologists treating colon cancer patients," stated one of the inventors, Dr. Mark Gustavson. "In addition, other proteins show differential cellular localization and the use of an expression ratio is applicable for development of other novel biomarkers for predicting outcome or therapeutic response."

About HistoRx, Inc.

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care.  The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA® technology.  AQUA® technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making.  HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care.  For more information, please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genoptix and HistoRx Announce Licensing Agreement for AQUA(R) Technology
2. HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research
3. HistoRx Names Bill Sullivan Senior Vice President, Diagnostic Operations
4. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
5. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
6. IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
7. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
8. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
9. Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee
10. LS9's UltraClean Diesel™ Receives EPA Registration
11. Drug Safety Firm BioSoteria Receives 2009 Best of Business Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS ... welcomed Abu Siddiqui as Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui ... translational biomarker discovery studies for preclinical and clinical safety programs. “We’ve seen significant ...
(Date:5/18/2016)... 18, 2016 The Biotech industry continues ... mean that there are no opportunities ahead. Today, ActiveWallSt.com has ... THLD ), Seattle Genetics Inc. (NASDAQ: ... Ophthotech Corp. (NASDAQ: OPHT ). Sign up now ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares ...
(Date:5/17/2016)... , May 18, 2016 Haselmeier ... prefilled pen following approval by EMA, the European Medicines ... science and technology company, the new pen version includes ... increased level of confidence to patients during use. ... prefilled pen easier to handle with a larger display ...
(Date:5/17/2016)... Switzerland , May 17, 2016 ... company located in Basel, Switzerland ... investigational oral inhibitor of P38 mitogen-activated protein kinase. ... , Strekin will build the necessary ... in indications in which MAP Kinases play fundamental ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):